VSA006
Asset
siRNA targeting HSD17B13 mRNA to downregulate hepatic HSD17B13 expression
- Stage
- Phase 2
- Modality
- Oligonucleotide
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1NASH
Phase 2, Active not recruiting, NCT06322628, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials1
Every asset’s record: target, stage, trials and the evidence behind it.